Mtbvac Tuberculosis Vaccine

• 27 Mar 2024

On 24th March, Bharat Biotech commenced clinical trials for Mtbvac, the first TB vaccine derived from a human source.

• Mtbvac developed for improved efficacy over BCG in newborns and prevention in adults.
• Trials conducted in collaboration with Biofabri; pivotal trial planned for 2025.
• India, with a high TB burden, crucial for testing adult and adolescent vaccines.
• Mtbvac marks significant progress in the quest for a more effective TB vaccine.
• Phase-3 clinical trials comparing Mtbvac with BCG initiated in newborns.